Nina Mamonova

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · New England Journal of Medicine · 2023 · 215 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +13

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · Journal of Hepatology · 2024 · 70 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +15

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · Journal of Hepatology · 2022 · 32 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +9

Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

Heiner Wedemeyer, Soo Aleman, Pietro Andreoné et al. · Digestive and Liver Disease · 2022 · 19 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +11

LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up

Heiner Wedemeyer, Soo Aleman, Antje Blank et al. · Journal of Hepatology · 2025 · 10 citations

Pharmacy, Pharmacotherapy, Hepatitis Pharmacotherapy +9